1. Genetic and epigenetic driven variation in regulatory regions activity contribute to adaptation and evolution under endocrine treatment
- Author
-
Neil Slaven, Rui Lopes, Eleonora Canale, Diana Ivanoiu, Claudia Pacini, Ines Amorim Monteiro Barbosa, Melusine Bleu, Sara Bravaccini, Sara Ravaioli, Maria Vittoria Dieci, Giancarlo Pruneri, Giorgio G. Galli, Iros Barozzi, and Luca Magnani
- Abstract
Comprehensive profiling of hormone-dependent breast cancer (HDBC) has identified hundreds of protein-coding alterations contributing to cancer initiation1, 2, but only a handful have been linked to endocrine therapy resistance, potentially contributing to 40% of relapses1, 3–9. If other mechanisms underlie the evolution of HDBC under adjuvant therapy is currently unknown. In this work, we employ integrative functional genomics to dissect the contribution of cis-regulatory elements (CREs) to cancer evolution by focusing on 12 megabases of non-coding DNA, including clonal enhancers10, gene promoters, and boundaries of topologically associating domains11. Massive parallel perturbation in vitro reveals context-dependent roles for many of these CREs, with a specific impact on dormancy entrance12, 13 and endocrine therapy resistance9. Profiling of CRE somatic alterations in a unique, longitudinal cohort of patients treated with endocrine therapies identifies non-coding changes involved in therapy resistance. Overall, our data uncover actionable transient transcriptional programs critical for dormant persister cells and unveil new regulatory nodes driving evolutionary trajectories towards disease progression.
- Published
- 2022